Cat. No. | Product name | CAS No. |
DC10100 |
Defactinib hydrochloride
Featured
Defactinib is a potent, selective, and orally active FAK inhibitor with demonstrated tolerability and preliminary clinical activity working as a single agent as well as in combination with paclitaxel. |
1073160-26-5 |
DC8300 |
Entrectinib (RXDX-101)
Featured
Entrectinib (RXDX-101), a potent and selective small molecule inhibitor of TrkA/B/C, ROS1, and ALK kinases, has demonstrated early clinical activity when orally administered intermittently under fasting conditions. |
1108743-60-7 |
DC2101 |
Erlotinib free base
Featured
Erlotinib (OSI-744; NSC 718781; R1415) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
183321-74-6 |
DC3139 |
Erlotinib hydrochloride
Featured
Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM. |
183319-69-9 |
DC7342 |
Foretinib(XL880)
Featured
Foretinib (GSK1363089; XL880; EXEL-2880; GSK089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM. Less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR. |
849217-64-7 |
DC2103 |
Gefitinib (ZD1839)
Featured
Gefitinib (Iressa, ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. |
184475-35-2 |
DC11543 |
Glumetinib
Featured
Glumetinib (SCC 244) is a novel potent and highly selective inhibitor of c-Met kinase with IC50 of 0.42 nM. |
1642581-63-2 |
DC8491 |
GSK2879552
Featured
GSK2879552 is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. |
1401966-69-5 |
DC7167 |
Capmatinib(INCB28060)
Featured
INCB28060 is a novel orally active inhibitor (IC50=0.13 nM) of c-MET kinase. |
1029712-80-8 |
DC7175 |
JNJ-26854165 (Serdemetan)
Featured
JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. |
881202-45-5 |
DC11900 |
Lazertinib
Featured
Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations |
1903008-80-9 |
DC11448 |
LOXO 195(Selitrectinib)
Featured
LOXO-195 is a next-generation TRK kinase (TKI) inhibitor, with IC50s of 0.6±0.1 nM, <2.5 nM for TRKA and TRKC respectively. |
2097002-61-2 |
DC10828 |
LXH254
Featured
LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254 also is a potent BRAF inhibitor. |
1800398-38-2 |
DC7993 |
Prexasertib (LY2606368) 2HCl
Featured
LY2606368 2Hcl is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase. |
1234015-54-3 |
DC10796 |
Prexasertib (LY2606368)
Featured
LY2606368 is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase. |
1234015-52-1 |
DC10219 |
LY3023414
Featured
LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK. |
1386874-06-1 |
DC8031 |
Marimastat
Marimastat is a broad spectrum MMP inhibitor and selective TACE inhibitor |
154039-60-8 |
DC1070 |
MK-1775(AZD-1775,Adavosertib)
Featured
MK-1775 is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM. |
955365-80-7 |
DC10282 |
ML385
Featured
ML385 is a novel and specific NRF2 inhibitor. |
846557-71-9 |
DC7200 |
Motesanib Diphosphate (AMG-706)
Featured
Motesanib (AMG-706) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more selective for VEGFR than PDGFR and Ret. |
857876-30-3 |
DC10284 |
Motesanib
Featured
Motesanib is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret. |
453562-69-1 |
DC7084 |
Nintedanib (BIBF 1120)
Featured
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM. |
656247-17-5 |